CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.

Kynan Feeney,Ronan J. Kelly,Lara Lipton,Joseph Chao,Mirelis Acosta-Rivera,Dennis Earle,Ming Lei,Georgia Kollia,Niall C. Tebbutt

CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.

2019

Kynan Feeney
Ronan J. Kelly
Lara Lipton
Joseph Chao
Mirelis Acosta-Rivera
Dennis Earle
Ming Lei
Georgia Kollia
Niall C. Tebbutt

TPS4143Background: Blockadeof the immune checkpointreceptor programmed death-1 (PD-1) has shown clinical benefit in multiple tumor types. Nivolumab(anti–PD-1) has demonstrated a survival advanta...

Keywords:

Nivolumab
Pathology
Gastroesophageal Junction Adenocarcinoma
Oncology
Internal medicine
Medicine
Chemotherapy
in patient
first line treatment
Immune checkpoint
Blockade
open label

Correction
Source
Cite
Save

References

Citations